GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » 14-Day RSI

CLVLF (Clinuvel Pharmaceuticals) 14-Day RSI : 14.74 (As of Dec. 13, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-13), Clinuvel Pharmaceuticals's 14-Day RSI is 14.74.

The industry rank for Clinuvel Pharmaceuticals's 14-Day RSI or its related term are showing as below:

CLVLF's 14-Day RSI is ranked better than
85.16% of 1523 companies
in the Biotechnology industry
Industry Median: 45.72 vs CLVLF: 14.74

Competitive Comparison of Clinuvel Pharmaceuticals's 14-Day RSI

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's 14-Day RSI falls into.



Clinuvel Pharmaceuticals  (OTCPK:CLVLF) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Clinuvel Pharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals Business Description

Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

From GuruFocus

Letter to shareholders from CLINUVEL's CEO

By GuruFocusNews GuruFocusNews 04-29-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-29-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-30-2022

PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation

By Marketwired Marketwired 07-13-2020

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-09-2022

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020